miR‑451a suppression of IL‑6R can inhibit proliferation and increase apoptosis through the JAK2/STAT3 pathway in multiple myeloma

Zhong,Ling; Xu,Zhuyu; Jin,Xin; He,Yuan; Zhang,Jianbo; Jiang,Tao; Chen,Jiao

doi:10.3892/ol.2020.12202

miR‑451a suppression of IL‑6R can inhibit proliferation and increase apoptosis through the JAK2/STAT3 pathway in multiple myeloma

Authors:
- Ling Zhong
- Zhuyu Xu
- Xin Jin
- Yuan He
- Jianbo Zhang
- Tao Jiang
- Jiao Chen
View Affiliations

Affiliations: Department of Clinical Laboratory, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China, Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China, Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: October 8, 2020 https://doi.org/10.3892/ol.2020.12202
Article Number: 339
Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The IL‑6R/JAK2/STAT3 pathway mediated by interleukin‑6 (IL‑6) plays an important role in the occurrence and development of multiple myeloma (MM), which is associated with decreased microRNA‑451a. However, the biological function of microRNA‑451a in MM remains unclear. The bone marrow (BM) of patients with MM was sampled, and the plasma cells were enriched. BM miR‑451a, IL‑6 and IL‑6R levels and Ki‑67 expression intensity were evaluated using reverse transcription‑quantitative PCR, ELISA and flow cytometry, respectively. U266 cell proliferation, viability and apoptosis were measured using BrdU, CCK‑8 and Annexin V/propidium iodide assays, respectively. Total and phospo‑(p‑)JAK2 and p‑STAT3 levels were measured by western blotting. Dual‑luciferase reporter assays were performed to validate the predicted target binding sites. miR‑451a expression was low in patients with MM and was associated with the Revised International Staging System (R‑ISS) stage. IL‑6 concentrations were significantly higher in patients with MM than in normal controls and were inversely associated with miR‑451a levels (r=‑0.96, P<0.0001). IL‑6R levels were positively correlated with the R‑ISS stage. miR‑451a was downregulated, and IL‑6R was upregulated in myeloma cell lines. Treatment with an miR‑451a mimic inhibited viability and induced apoptosis in U266 cells. p‑JAK2 and p‑STAT3 levels were significantly lower in mimic‑treated U266 cells than in control cells. Thus, miR‑451a was shown to regulate myeloma cell proliferation and apoptosis via the IL‑6R/JAK2/STAT3 pathway and may be used to predict patient prognosis.

View Figures

View References

1	Chang SH, Luo S, Thomas TS, O'Brian KK, Colditz GA, Carlsson NP and Carson KR: Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based cohort study. J Natl Cancer Inst. 109:djw2642016. View Article : Google Scholar
2	Popovic M, Lao N, Bedard G, Zeng L, Zhang L, Cella D, Beaumont JL, Chiu N, Chiu L, Lam H, et al: Quality of life in patients with advanced cancer using the functional assessment of cancer therapy-general assessment tool: A literature review. World J Oncol. 4:8–17. 2013.PubMed/NCBI
3	Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, et al: Clinical utility of the revised international staging system in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 7:e5282017. View Article : Google Scholar : PubMed/NCBI
4	Furukawa M, Ohkawara H, Ogawa K, Ikeda K, Ueda K, Shichishima-Nakamura A, Ito E, Imai JI, Yanagisawa Y, Honma R, et al: Autocrine and paracrine interactions between multiple myeloma cells and bone marrow stromal cells by growth arrest-specific gene 6 cross-talk with interleukin-6. J Biol Chem. 292:4280–4292. 2017. View Article : Google Scholar : PubMed/NCBI
5	Mishra AK and Dingli D: Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 33:2695–2709. 2019. View Article : Google Scholar : PubMed/NCBI
6	De Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE and Colleoni GWB: Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 403:206–215. 2017. View Article : Google Scholar : PubMed/NCBI
7	Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T and Margalit H: Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 33:2697–2706. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wang R, Wang ZX, Yang JS, Pan X, De W and Chen LB: MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
9	Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W, et al: MicroRNA-451: Epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocellular carcinoma. Oncotarget. 6:18613–18630. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kim Y, Powathil G, Kang H, Trucu D, Kim H, Lawler S and Chaplain M: Strategies of eradicating glioma cells: A multi-scale mathematical model with MiR-451-AMPK-mTOR control. PLoS One. 10:e1143702015.
11	Yuan J, Lang J, Liu C, Zhou K, Chen L and Liu Y: The expression and function of miRNA-451 in osteosarcoma. Med Oncol. 32:3242015. View Article : Google Scholar : PubMed/NCBI
12	Gits CM, van Kuijk PF, Jonkers MB, Boersma AWM, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C, Mathijssen RHJ, et al: MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer. 135:348–361. 2014. View Article : Google Scholar : PubMed/NCBI
13	Liu X, Zhang A, Xiang J, Lv Y and Zhang X: miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep. 36:1385–1392. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, et al: IMWG consensus on risk stratification in multiple myeloma. Leukemia. 28:269–277. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et al: International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17:e328–e346. 2016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, et al: Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 31:2094–2103. 2017. View Article : Google Scholar : PubMed/NCBI
18	Kolosenko I, Grander D and Tamm KP: IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma. Curr Med Chem. 21:3042–3047. 2014. View Article : Google Scholar : PubMed/NCBI
19	Liu X, Wang J, Wang H, Yin G, Liu Y, Lei X and Xiang M: REG3A accelerates pancreatic cancer cell growth under IL-6-associated inflammatory condition: Involvement of a REG3A-JAK2/STAT3 positive feedback loop. Cancer Lett. 362:45–60. 2015. View Article : Google Scholar : PubMed/NCBI
20	Suematsu S, Hibi M, Sugita T, Saito M, Murakami M, Matsusaka T, Matsuda T, Hirano T, Taga T and Kishimoto T: Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma. Curr Top Microbiol Immunol. 166:13–22. 1990.PubMed/NCBI
21	Piddock RE, Marlein CR, Abdul-Aziz A, Shafat MS, Auger MJ, Bowles KM and Rushworth SA: Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC. J Hematol Oncol. 11:66–69. 2018. View Article : Google Scholar : PubMed/NCBI
22	Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, et al: Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the multiple myeloma cohort consortium. Blood. 120:4929–4937. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhao S, Li J, Zhang G, Wang Q, Wu C, Zhang Q, Wang H, Sun P, Xiang R and Yang S: Exosomal miR-451a functions as a tumor suppressor in hepatocellular carcinoma by targeting LPIN1. Cell Physiol Biochem. 53:19–35. 2019. View Article : Google Scholar : PubMed/NCBI
24	Meng YB, He X, Huang YF, Wu QN, Zhou YC and Hao DJ: Long noncoding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451. Oncol Res. 25:1207–1214. 2017. View Article : Google Scholar : PubMed/NCBI
25	Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR and Pillai MM: Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells. 32:662–673. 2014. View Article : Google Scholar : PubMed/NCBI
26	Liu SY, Deng SY, He YB and Ni GX: miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL-6R. Biochem Biophys Res Commun. 482:987–993. 2017. View Article : Google Scholar : PubMed/NCBI
27	Gocke CB, McMillan R, Wang Q, Begum A, Penchev VR, Ali SA, Borrello I, Huff CA and Matsui W: IQGAP1 scaffold-MAP kinase interactions enhance multiple myeloma clonogenic growth and self-renewal. Mol Cancer Ther. 15:2733–2739. 2016. View Article : Google Scholar : PubMed/NCBI
28	Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, et al: Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 74:4458–4469. 2014. View Article : Google Scholar : PubMed/NCBI
29	Berenstein R, Nogai A, Waechter M, Blau O, Kuehnel A, Schmidt-Hieber M, Kunitz A, Pezzutto A, Dörken B and Blau IW: Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223. Mol Carcinog. 55:1927–1939. 2016. View Article : Google Scholar : PubMed/NCBI
30	Matthews GM, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, Sorrell JD and Mitsiades CS: NF-κB dysregulation in multiple myeloma. Semin Cancer Biol. 39:68–76. 2016. View Article : Google Scholar : PubMed/NCBI